Insmed, Inc. (NASDAQ:INSM) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Insmed, Inc. (NASDAQ:INSM) has been given a consensus recommendation of “Moderate Buy” by the sixteen research firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and fifteen have issued a buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $129.5714.

INSM has been the topic of several research analyst reports. Stifel Nicolaus increased their price target on Insmed from $121.00 to $145.00 and gave the company a “buy” rating in a report on Thursday, August 14th. Mizuho increased their price target on Insmed from $130.00 to $165.00 and gave the company an “outperform” rating in a report on Wednesday, August 13th. Jefferies Financial Group increased their price target on Insmed from $129.00 to $148.00 and gave the company a “buy” rating in a report on Wednesday, August 13th. Morgan Stanley reissued an “equal weight” rating and set a $126.00 price target on shares of Insmed in a report on Wednesday, August 13th. Finally, Wells Fargo & Company increased their price target on Insmed from $130.00 to $140.00 and gave the company an “overweight” rating in a report on Tuesday, August 12th.

Insider Buying and Selling

In related news, Director David W. J. Mcgirr sold 3,250 shares of the firm’s stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $71.30, for a total value of $231,725.00. Following the transaction, the director directly owned 100,723 shares of the company’s stock, valued at approximately $7,181,549.90. This trade represents a 3.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO William Lewis sold 129,805 shares of the firm’s stock in a transaction on Monday, June 16th. The stock was sold at an average price of $100.39, for a total value of $13,031,123.95. Following the completion of the transaction, the chief executive officer directly owned 233,924 shares in the company, valued at approximately $23,483,630.36. This represents a 35.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 497,829 shares of company stock valued at $47,778,638 in the last 90 days. 3.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Insmed

A number of institutional investors have recently bought and sold shares of INSM. M&T Bank Corp increased its holdings in shares of Insmed by 4.7% in the first quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company’s stock worth $252,000 after purchasing an additional 147 shares during the last quarter. Snowden Capital Advisors LLC boosted its position in shares of Insmed by 2.5% during the 4th quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company’s stock valued at $456,000 after acquiring an additional 158 shares during the last quarter. First Horizon Advisors Inc. grew its holdings in shares of Insmed by 24.8% in the second quarter. First Horizon Advisors Inc. now owns 936 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 186 shares in the last quarter. ORG Partners LLC grew its holdings in shares of Insmed by 220.2% in the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 196 shares in the last quarter. Finally, Cullen Frost Bankers Inc. grew its holdings in shares of Insmed by 164.9% in the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 221 shares in the last quarter.

Insmed Stock Performance

Insmed stock opened at $127.21 on Wednesday. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $26.89 billion, a P/E ratio of -22.28 and a beta of 0.95. The stock’s 50 day moving average is $105.47 and its 200 day moving average is $84.62. Insmed has a twelve month low of $60.40 and a twelve month high of $130.13.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The company had revenue of $107.42 million during the quarter, compared to analysts’ expectations of $104.06 million. During the same quarter in the previous year, the company earned ($1.94) EPS. The business’s quarterly revenue was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Insmed will post -4.56 earnings per share for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.